|Venture Round, 7/12 ||$40M|
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, a drug is released on a controlled and level basis for months or years. The Company has two core technology systems, Durasert and BioSilicon. pSivida Corp. has one product candidate for chronic eye disease that has been given Priority Review by the United States Food and Drug Administration (FDA). It has a collaboration with Pfizer, Inc. (Pfizer) to develop additional ophthalmic products. Iluvien, the product candidiate with Priority Review, is designed to provide sustained release treatment for Diabetic Macula Edema (DME). Iluvien is licensed to Alimera Sciences, Inc (Alimera), which is completing fully-recruited Phase III clinical trials.